Europe Brain Cancer Epidemiology and Patient Flow Analysis - 2017

Europe Brain Cancer Epidemiology and Patient Flow Analysis - 2017

Fore Pharma announced the results of its Brain Cancer patients study in a new report ‘Europe Brain Cancer Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Brain Cancer epidemiology, Brain Cancer diagnosed patients, and Brain Cancer treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Brain Cancer derived from epidemiological analysis, percentage of patients diagnosed with Brain Cancer, and percentage of patients treated with a therapy.

The study helps executives estimate Brain Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Brain Cancer prevalence, Brain Cancer diagnosis rate, and Brain Cancer treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:

• Brain Cancer Patient Flow
• Brain Cancer Prevalence
• Brain Cancer Diagnosed Patients
• Brain Cancer Treated Patients